Targeting two pathways to treat aggressive breast cancer
Dual inhibition of PARP and STAT3 as a novel therapeutic approach for triple-negative breast cancer
This study is exploring a new treatment for triple-negative breast cancer that aims to make current therapies work better by targeting specific proteins, and it could be especially helpful for patients with BRCA mutations.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11012868 on NIH RePORTER |
What this research studies
This research investigates a new treatment approach for triple-negative breast cancer (TNBC), a particularly aggressive form of breast cancer with limited effective therapies. The study aims to inhibit two key proteins, PARP and STAT3, which are involved in cancer cell survival and resistance to treatment. By targeting these proteins, the researchers hope to enhance the effectiveness of existing therapies and reduce cancer cell growth. Patients with TNBC, especially those with BRCA mutations, may benefit from this innovative combination therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer, particularly those with BRCA mutations.
Not a fit: Patients with non-breast cancers or those with other subtypes of breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with triple-negative breast cancer.
How similar studies have performed: Other research has shown promising results with similar dual-targeting approaches in cancer treatment, indicating potential for success in this novel application.
Where this research is happening
Baltimore, United States
- University of Maryland Baltimore — Baltimore, United States (Active)
Researchers
- Principal investigator: Lin, Jiayuh — University of Maryland Baltimore
- Study coordinator: Lin, Jiayuh
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.